ThromboGenics completes enrollment for phase 3 MIVI-TRUST program.
- Published in:
- Ocular Surgery News, 2010, v. 28, n. 2, p. 38
- Publication type:
- Article
Works matching DE "THROMBOGENICS NV"
Results: 7
1
2
Deal watch: Alcon invests in first non-surgical therapy for common eye disorder.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 342, doi. 10.1038/nrd3736
- By:
- Publication type:
- Article
3
Roche consolidates grip on anti-angiogenesis market.
- Published in:
- Nature Biotechnology, 2008, v. 26, n. 10, p. 1055, doi. 10.1038/nbt1008-1055
- By:
- Publication type:
- Article
4
Truncated plasmin derivative for treating vitreomacular adhesion now supported by two Phase III trials.
- Published in:
- Expert Review of Ophthalmology, 2010, v. 5, n. 5, p. 593
- Publication type:
- Article
5
MANAGING VITREOMACULAR ADHESION.
- Published in:
- Optometry Times, 2013, p. 1
- By:
- Publication type:
- Article
6
Going it alone.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 5, p. 411, doi. 10.1038/nbt.2896
- Publication type:
- Article
7
Belgian biotech's clot-buster approved for aging eyes.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 12, p. 1158, doi. 10.1038/nbt1212-1158b
- By:
- Publication type:
- Article